Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sharon Callison

Obstetrics & Gynecology Huntsville, AL Medical Doctor

NPI 1013901107 CMS profile 904373

910 Adams St Se, #200, Huntsville, AL 35801

Open in the dashboard

General payments

$2,260

131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sharon Callison of Huntsville, AL is reported in the CMS Open Payments database as having received $2,260 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $358 17
2024 General $160 10
2023 General $439 26
2022 General $340 21
2021 General $586 34
2020 General $192 11
2019 General $186 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sharon Callison
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Sharon Callison were reported at $358. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Sharon Callison Obstetrics & Gynecology median Middle half National median
2019 $186 $172 $62–$391 $163
2020 $192 $94 $36–$222 $114
2021 $586 $136 $42–$369 $132
2022 $340 $160 $50–$433 $149
2023 $439 $169 $56–$423 $160
2024 $160 $152 $50–$371 $164
2025 $358 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $412 32 payments
  2. Sumitomo Pharma America, Inc. $222 13 payments
  3. Intuitive Surgical, Inc. $216 8 payments
  4. Sage Therapeutics, Inc. $192 9 payments
  5. Hologic, LLC $157 7 payments
  6. Myovant Sciences Inc. $156 10 payments
  7. Astellas Pharma US Inc $126 7 payments
  8. Pfizer Inc. $70 4 payments
  9. Vermillion, Inc. $60 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $53 3 payments
  11. Other $596 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,246 130 payments
  2. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. MYFEMBREE $358 22 payments
  2. Da Vinci Surgical System $216 8 payments
  3. LO LOESTRIN FE $199 11 payments
  4. ZURZUVAE $192 9 payments
  5. ORILISSA Womens Health $139 15 payments
  6. Veozah $126 7 payments
  7. ORIAHNN $103 12 payments
  8. Orilissa Endocrinology $94 6 payments
  9. MYOSURE TISSUE REMOVAL DEVICE $65 1 payment
  10. OVA1 $60 1 payment
  11. Other $1,083 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record